Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. more
Time Frame | XBIO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.93% | -3.35% | -2.97% |
1-Month Return | 9.74% | -3.49% | -0.66% |
3-Month Return | 14.13% | -12.6% | 2.71% |
6-Month Return | 6.6% | -6.91% | 7.21% |
1-Year Return | 22.64% | 1.19% | 23.04% |
3-Year Return | -69.65% | -0.21% | 28.43% |
5-Year Return | -70.48% | 33.09% | 82.88% |
10-Year Return | -99.38% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 17.07K | 436.94K | 1.16M | 1.71M | 2.54M | [{"date":"2019-12-31","value":0.67,"profit":true},{"date":"2020-12-31","value":17.2,"profit":true},{"date":"2021-12-31","value":45.7,"profit":true},{"date":"2022-12-31","value":67.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | - | 35.48K | 27.04K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.22,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 17.07K | 436.94K | 1.13M | 1.68M | 2.54M | [{"date":"2019-12-31","value":0.67,"profit":true},{"date":"2020-12-31","value":17.2,"profit":true},{"date":"2021-12-31","value":44.3,"profit":true},{"date":"2022-12-31","value":66.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 96.94% | 98.42% | 100.00% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.94,"profit":true},{"date":"2022-12-31","value":98.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 9.62M | 5.13M | 6.91M | 8.42M | 7.06M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":53.34,"profit":true},{"date":"2021-12-31","value":71.8,"profit":true},{"date":"2022-12-31","value":87.57,"profit":true},{"date":"2023-12-31","value":73.34,"profit":true}] |
Operating Income | (12.89M) | 4.55M | (5.75M) | (6.72M) | (4.52M) | [{"date":"2019-12-31","value":-283.31,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-126.34,"profit":false},{"date":"2022-12-31","value":-147.69,"profit":false},{"date":"2023-12-31","value":-99.28,"profit":false}] |
Total Non-Operating Income/Expense | 220.29K | 251.85K | 202.05K | 332.71K | 732.94K | [{"date":"2019-12-31","value":30.06,"profit":true},{"date":"2020-12-31","value":34.36,"profit":true},{"date":"2021-12-31","value":27.57,"profit":true},{"date":"2022-12-31","value":45.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (12.78M) | (13.81M) | (5.65M) | (6.55M) | (4.13M) | [{"date":"2019-12-31","value":-1277502500,"profit":false},{"date":"2020-12-31","value":-1381198400,"profit":false},{"date":"2021-12-31","value":-564517900,"profit":false},{"date":"2022-12-31","value":-655235300,"profit":false},{"date":"2023-12-31","value":-413457800,"profit":false}] |
Income Taxes | 3.17M | (2.92M) | (100.47K) | (165.56K) | 28.21K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-91.93,"profit":false},{"date":"2021-12-31","value":-3.16,"profit":false},{"date":"2022-12-31","value":-5.21,"profit":false},{"date":"2023-12-31","value":0.89,"profit":true}] |
Income After Taxes | (15.95M) | (10.89M) | (5.54M) | (6.39M) | (4.16M) | [{"date":"2019-12-31","value":-1594991500,"profit":false},{"date":"2020-12-31","value":-1089346600,"profit":false},{"date":"2021-12-31","value":-554471200,"profit":false},{"date":"2022-12-31","value":-638679800,"profit":false},{"date":"2023-12-31","value":-416278500,"profit":false}] |
Income From Continuous Operations | (12.78M) | (10.89M) | (5.65M) | (6.55M) | (4.45M) | [{"date":"2019-12-31","value":-1277502500,"profit":false},{"date":"2020-12-31","value":-1089346600,"profit":false},{"date":"2021-12-31","value":-564517900,"profit":false},{"date":"2022-12-31","value":-655235300,"profit":false},{"date":"2023-12-31","value":-444560700,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (15.95M) | (10.89M) | (5.54M) | (6.39M) | (4.13M) | [{"date":"2019-12-31","value":-1594991500,"profit":false},{"date":"2020-12-31","value":-1089346600,"profit":false},{"date":"2021-12-31","value":-554471200,"profit":false},{"date":"2022-12-31","value":-638679800,"profit":false},{"date":"2023-12-31","value":-413457800,"profit":false}] |
EPS (Diluted) | (3.39) | (0.23) | (0.55) | (0.47) | (2.75) | [{"date":"2019-12-31","value":-339,"profit":false},{"date":"2020-12-31","value":-23,"profit":false},{"date":"2021-12-31","value":-55,"profit":false},{"date":"2022-12-31","value":-47,"profit":false},{"date":"2023-12-31","value":-275,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
XBIO | |
---|---|
Cash Ratio | 6.78 |
Current Ratio | 6.96 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
XBIO | |
---|---|
ROA (LTM) | -28.74% |
ROE (LTM) | -48.61% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
XBIO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.13 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.87 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
XBIO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2.48 |
P/B | 0.89 |
Price/FCF | NM |
EV/R | 0.02 |
EV/Ebitda | 1.03 |
PEG | NM |
Xenetic Biosciences Inc (XBIO) share price today is $4.28
Yes, Indians can buy shares of Xenetic Biosciences Inc (XBIO) on Vested. To buy Xenetic Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XBIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Xenetic Biosciences Inc (XBIO) via the Vested app. You can start investing in Xenetic Biosciences Inc (XBIO) with a minimum investment of $1.
You can invest in shares of Xenetic Biosciences Inc (XBIO) via Vested in three simple steps:
The 52-week high price of Xenetic Biosciences Inc (XBIO) is $5.2. The 52-week low price of Xenetic Biosciences Inc (XBIO) is $2.78.
The price-to-earnings (P/E) ratio of Xenetic Biosciences Inc (XBIO) is
The price-to-book (P/B) ratio of Xenetic Biosciences Inc (XBIO) is 0.89
The dividend yield of Xenetic Biosciences Inc (XBIO) is 0.00%
The market capitalization of Xenetic Biosciences Inc (XBIO) is $6.26M
The stock symbol (or ticker) of Xenetic Biosciences Inc is XBIO